BIOA-B and BIOAB Related Headlines
Go Back- More than 75% of Leqembi®-treated patients remained stable and nearly 7% improved over an average of 17 months of treatment in real-world LEADER study data presented at AAIC® 2026
- FDA clears Leqembi Iqlik subcutaneous shot as Alzheimer's start dose
- FDA approves Leqembi Iqlik® (lecanemab-irmb) subcutaneous injection as a starting dose for early Alzheimer's disease
- New clinical data on the Leqembi® subcutaneous autoinjector presented at AAIC® 2026 support similar efficacy and safety to IV formulation in early Alzheimer's disease
- BioArctic publishes the Annual Report and Sustainability Report for 2025
- New data on long-term, real-world treatment with lecanemab presented at the 2026 AD/PD™ congress
- Leqembi® Iqlik™ (lecanemab-irmb) maintenance treatment launched in the U.S.
- Leqembi® approved for IV maintenance treatment in China
- BioArctic's founders intend to divest minor part of their shareholding
BIOA-B and BIOAB Related Press Releases
Go Back- More than 75% of Leqembi®-treated patients remained stable and nearly 7% improved over an average of 17 months of treatment in real-world LEADER study data presented at AAIC® 2026
- FDA approves Leqembi Iqlik® (lecanemab-irmb) subcutaneous injection as a starting dose for early Alzheimer's disease
- New clinical data on the Leqembi® subcutaneous autoinjector presented at AAIC® 2026 support similar efficacy and safety to IV formulation in early Alzheimer's disease
- BioArctic publishes the Annual Report and Sustainability Report for 2025
- New data on long-term, real-world treatment with lecanemab presented at the 2026 AD/PD™ congress
- Leqembi® Iqlik™ (lecanemab-irmb) maintenance treatment launched in the U.S.
- Leqembi® approved for IV maintenance treatment in China
- BioArctic's founders intend to divest minor part of their shareholding
